Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust ...

Maximal level of SRC inhibition in patient samples after a single dose of NXP900 exceeded 90%. Three preclinical posters highlight ... ,“This year's AACR presentations mark an important ...

("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design ...

Researchers are just beginning to understand how microplastics might be affecting human health. A Reporter visited a lab to ...

Canva Code is one of the newest features Canva is rolling out and I have to say, I find it genuinely helpful. With Canva Code ...

TP53 mutations are a critical biomarker in hematolymphoid malignancies. P53 immunohistochemistry (IHC) is routinely used in clinical laboratories to rapidly screen tumor samples for TP53 gene ...

Patients with advanced chronic kidney disease are at increased risk of hemorrhagic peptic ulcer disease hospitalization and adverse outcomes.

Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from ...